依鲁替尼——首创药物,每天口服一次,布鲁顿酪氨酸激酶(BTK)的共价抑制剂——口服给药之后可快速从浆细胞内清除。
Ibrutinib (ibr), a first-in-class, once-daily, oral, covalent inhibitor of Bruton's tyrosine kinase (BTK), is rapidly eliminated from plasma after oral administration (Advani, JCO 2013).
依鲁替尼——首创药物,每天口服一次,布鲁顿酪氨酸激酶(BTK)的共价抑制剂——口服给药之后可快速从浆细胞内清除。
Ibrutinib (ibr), a first-in-class, once-daily, oral, covalent inhibitor of Bruton's tyrosine kinase (BTK), is rapidly eliminated from plasma after oral administration (Advani, JCO 2013).
应用推荐